Teva Pharmaceutical Industries Ltd. $TEVA Stock: Ethic Inc. Boosts Stake

Ethic Inc. boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 63.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 33,024 shares of the company’s stock after purchasing an additional 12,853 shares during the quarter. Ethic Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,308,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in TEVA. Parallel Advisors LLC lifted its position in shares of Teva Pharmaceutical Industries by 8.7% in the 3rd quarter. Parallel Advisors LLC now owns 4,626 shares of the company’s stock worth $183,000 after purchasing an additional 370 shares during the period. Kestra Advisory Services LLC grew its stake in shares of Teva Pharmaceutical Industries by 16.6% in the third quarter. Kestra Advisory Services LLC now owns 53,716 shares of the company’s stock worth $2,127,000 after acquiring an additional 7,631 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries by 1.5% in the third quarter. Commonwealth Equity Services LLC now owns 133,416 shares of the company’s stock worth $5,283,000 after buying an additional 1,965 shares during the last quarter. Rakuten Investment Management Inc. lifted its position in Teva Pharmaceutical Industries by 13.0% in the 3rd quarter. Rakuten Investment Management Inc. now owns 76,883 shares of the company’s stock valued at $3,061,000 after acquiring an additional 8,865 shares in the last quarter. Finally, Signaturefd LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 9.6% during the third quarter. Signaturefd LLC now owns 17,329 shares of the company’s stock valued at $686,000 after purchasing an additional 1,520 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Key Stories Impacting Teva Pharmaceutical Industries

Here are a few of the latest stories about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Wall Street Analysts Forecast Growth

TEVA has been the subject of a number of recent research reports. Zacks Research downgraded Teva Pharmaceutical Industries from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 20th. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Leerink Partners increased their price target on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, November 5th. Finally, HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a report on Monday, November 2nd. They issued a “buy” rating and a $52.00 target price for the company. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $48.15.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 250,000 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $42.24, for a total value of $10,560,000.00. Following the completion of the sale, the chief executive officer owned 927,529 shares of the company’s stock, valued at $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Richard Daniell sold 20,003 shares of the stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $42.80, for a total value of $856,128.40. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at approximately $2,386,314. This represents a 26.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 715,945 shares of company stock worth $29,061,351. 0.54% of the stock is owned by company insiders.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $44.52 on Friday. Teva Pharmaceutical Industries Ltd. has a 12 month low of $24.01 and a 12 month high of $44.57. The company has a debt-to-equity ratio of 1.59, a current ratio of 0.95 and a quick ratio of 0.74. The firm’s 50-day moving average is $40.16 and its two-hundred day moving average is $35.07. The company has a market capitalization of $51.88 billion, a PE ratio of 103.53, a price-to-earnings-growth ratio of 4.09 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion for the quarter, compared to analysts’ expectations of $4.23 billion. During the same quarter last year, the company earned $0.78 earnings per share. The firm’s revenue was down 1.9% compared to the same quarter last year. Analysts predict that Teva Pharmaceutical Industries Ltd. will post 1.98 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.